Effective products for chemistry professionals worldwide

Biotage AB (publ) – disclosure notice of substantial holding of shares

Biotage AB – changes in number of shares and votes

Biotage AB launches share buy-back

Biotage breaks new ground with its fully integrated mass directed flash system

Biotage and Peptide Synthesis

Coming soon: Isolera™ Dalton - Flash Chromatography with Integrated Mass Identification

ISOLUTE® Myco SPE columns, a dedicated product for the efficient extraction of mycotoxins from food matrices

TLC-to-Step Gradient capability significantly reduces both purification time and solvent use

Biotage Releases New Catalog and Technical Guide for Sample Preparation and Evaporation

	[2012-04-05 09:00] Biotage AB (publ) publishes its 2011 Annual Report and Corporate Governance Report As from today, Biotage’s Annual Report and Corporate Governance Report for 2011 are available at: www.biotage.com Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 09.00 on April 5 2012. Contact: Torben Jörgensen, President and CEO Tel: +46 707 49 05 84, torben.jorgensen@biotage.com About Biotage Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world’s largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has 270 employees and had sales of 428.4 MSEK in 2011. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com The following files are available for download: Press release in html format
	Print page